Department of Oncology, Third Hospital of Qinhuangdao, Qinhuangdao, China.
Hepatology Department, The Third People's Hospital of Taiyuan, Taiyuan, China.
Indian J Cancer. 2021 Jan-Mar;58(1):57-61. doi: 10.4103/ijc.IJC_635_18.
This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either I seed implantation or I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with I seed implantation therapy. The therapy group (n = 50) was treated with an intra-tumor injection of cisplatin along with TACE and I seed implantation therapy. After treatment, routine blood, liver and kidney function, tumor volume, T lymphocyte subset count (CD3, CD4, and CD8), implanted metastases, and survival were studied.
The tumor volume decreased by 27.4% on average in the control group, and by 38.6% in the therapy group. Alpha fetoprotein (AFP) level decreased in all cases, and it was significantly lower in the therapy group than in the control group. Remote metastasis was observed in both groups (7 in the control group and 3 in the therapy group). No significant difference in routine blood, liver and kidney function, and T-lymphocyte subset counts were found between the two groups. Eight patients died of metastases in the control group and 2 in the therapy group at 1-year follow-up (P < 0.05).
TACE combined with either I seed implantation or I seed implantation and intra-tumor injection of cisplatin was effective for the treatment of HCC. Of the 2 combination therapies, TACE combined with I seed implantation and intra-tumor injection of cisplatin was more effective for the treatment of HCC.
本研究旨在比较经导管动脉化疗栓塞（TACE）联合(125)I 粒子植入或 TACE 联合(125)I 粒子植入及瘤内注射顺铂治疗肝细胞癌（HCC）的疗效。
共分析 100 例 HCC 患者。对照组（n=50）接受 TACE 联合(125)I 粒子植入治疗。治疗组（n=50）采用顺铂瘤内注射联合 TACE 和(125)I 粒子植入治疗。治疗后检测常规血液、肝肾功能、肿瘤体积、T 淋巴细胞亚群（CD3、CD4 和 CD8）计数、种植转移和生存情况。
对照组肿瘤体积平均缩小 27.4%，治疗组缩小 38.6%。两组甲胎蛋白（AFP）水平均下降，治疗组明显低于对照组。两组均有远处转移（对照组 7 例，治疗组 3 例）。两组常规血液、肝肾功能和 T 淋巴细胞亚群计数无显著差异。对照组有 8 例患者在 1 年随访时因转移而死亡，治疗组有 2 例（P<0.05）。
TACE 联合(125)I 粒子植入或 TACE 联合(125)I 粒子植入及瘤内注射顺铂治疗 HCC 均有效。在 2 种联合治疗中，TACE 联合~(125)I 粒子植入及瘤内注射顺铂治疗 HCC 的效果更好。
